ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity
Cellular Oncology · 2025-02 · 48 (1) · 83-99
DOI: 10.1007/s13402-024-00957-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 31.05.2024. Verfasst von Irene Zamora und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Public University of Navarre, Pamplona, Navarre, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Transcription Factors, Cell Plasticity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Pública de Navarra.
Abstract (Originalsprache)
Purpose
Tumor heterogeneity complicates patient treatment and can be due to transitioning of cancer cells across phenotypic cell states. This process is associated with the acquisition of independence from an oncogenic driver, such as the estrogen receptor (ER) in breast cancer (BC), resulting in tumor progression, therapeutic failure and metastatic spread. The transcription factor ONECUT2 (OC2) has been shown to be a master regulator protein of metastatic castration-resistant prostate cancer (mCRPC) tumors that promotes lineage plasticity to a drug-resistant neuroendocrine (NEPC) phenotype. Here, we investigate the role of OC2 in the dynamic conversion between different molecular subtypes in BC.
Methods
We analyze OC2 expression and clinical significance in BC using public databases and immunohistochemical staining. In vitro , we perform RNA-Seq, RT-qPCR and western-blot after OC2 enforced expression. We also assess cellular effects of OC2 silencing and inhibition with a drug-like small molecule in vitro and in vivo .
Results
OC2 is highly expressed in a substantial subset of hormone receptor negative human BC tumors and tamoxifen-resistant models, and is associated with poor clinical outcome, lymph node metastasis and heightened clinical stage. OC2 inhibits ER expression and activity, suppresses a gene expression program associated with luminal differentiation and activates a basal-like state at the gene expression level. We also show that OC2 is required for cell growth and survival in metastatic BC models and that it can be targeted with a small molecule inhibitor providing a novel therapeutic strategy for patients with OC2 active tumors.
Conclusions
The transcription factor OC2 is a driver of BC heterogeneity and a potential drug target in distinct cell states within the breast tumors. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, Public University of Navarre, Pamplona, Navarre, Spain.
- IdiSNA, Navarre Institute for Health Research, Pamplona, Navarre, Spain.
- Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Department of Pathology, University of Utah, Salt Lake City, UT, USA.
- Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
- Department of Health Sciences, Public University of Navarre, Pamplona, Navarre, Spain. mirja.rotinen@unavarra.es.
Förderung
- Universidad Pública de Navarra
Zitieren
APA
Zamora, I., Gutiérrez, M., Pascual, A., Pajares, M. J., Barajas, M., Perez, L. M., You, S., Knudsen, B. S., Freeman, M. R., Encío, I. J., & Rotinen, M. (2025). ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity. Cellular Oncology, 48(1), 83-99. https://doi.org/10.1007/s13402-024-00957-3
Vancouver
Zamora I, Gutiérrez M, Pascual A, Pajares MJ, Barajas M, Perez LM, et al. ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity. Cellular Oncology. 2025;48(1):83-99. doi:10.1007/s13402-024-00957-3
BibTeX
@article{Zamora2025,
author = {Zamora, Irene and Gutiérrez, Mirian and Pascual, Alex and Pajares, María J and Barajas, Miguel and Perez, Lillian M and You, Sungyong and Knudsen, Beatrice S and Freeman, Michael R and Encío, Ignacio J and Rotinen, Mirja},
title = {ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity},
journal = {Cellular Oncology},
year = {2025},
volume = {48},
number = {1},
pages = {83--99},
doi = {10.1007/s13402-024-00957-3}
}
EUVIMED